Servier's $1.55B muscular dystrophy drug fails pivotal trial

· Health · France

Servier's acquired muscular dystrophy drug sevasemten has failed its pivotal GRAND CANYON trial, missing both primary and secondary endpoints, roughly five months after the French drugmaker paid $1.55 billion upfront to Edgewise Therapeutics for it. The failure is a surprise setback for a form of muscular dystrophy that currently lacks any approved treatment. The asset was viewed as a late-stage bet on a rare neuromuscular disease with high unmet need. The immediate effect is a major blow to Servier's late-stage pipeline and to the commercial case behind one of the larger upfront payments in recent rare-disease dealmaking; the result also casts doubt on the program's path toward approval.

Why it matters：It shows how quickly large upfront rare-disease bets can sour, and removes a would-be first therapy for a disease with no approved options, affecting patients, investors and future deal pricing.

Key points

  • Sevasemten failed both primary and secondary endpoints in the GRAND CANYON pivotal trial.
  • Servier paid $1.55 billion upfront to Edgewise Therapeutics for the drug.
  • The failure came about five months after the deal closed.

Sources (original reporting)

More stories from this day